---
title: "Pre-market hot trades in US stocks: POET Tech pre-market down 7.80%; Scinai Immunotherapeutics pre-market down 7.73%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284346105.md"
description: "POET Tech pre-market down 7.80%; Scinai Immunotherapeutics pre-market down 7.73%; Direct Digital pre-market up 45.22%; Calidi Biotherapeutics pre-market up 39.24%; Profusa pre-market up 28.36%"
datetime: "2026-04-28T09:47:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284346105.md)
  - [en](https://longbridge.com/en/news/284346105.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284346105.md)
---

# Pre-market hot trades in US stocks: POET Tech pre-market down 7.80%; Scinai Immunotherapeutics pre-market down 7.73%

**Pre-market Hot Trades in US Stocks**

POET Tech is down 7.80% in pre-market trading. Based on recent key news:

1.  On April 27, POET Technologies had all orders canceled by Marvell for violating a confidentiality agreement, causing its stock price to plummet by 47.7%. Marvell accused POET of leaking purchase orders and shipping information, leading to a loss of market confidence, with the stock closing at $7.95. Source: Reuters
    
2.  On April 27, POET Technologies' stock price fell by 40.60% in pre-market trading, reflecting market concerns about its future prospects. Source: Benzinga
    
3.  On April 28, global energy and AI markets are turbulent, affecting investor confidence. Brent crude futures returned to $100 per barrel, and the AI industry faces legal challenges, requiring close attention to these factors' impact on the economy. Source: Wall Street Insight AI industry faces legal challenges, market volatility intensifies.
    

Scinai Immunotherapeutics is down 7.73% in pre-market trading. Based on recent key news:

1.  On April 25, Scinai Immunotherapeutics announced a securities purchase agreement, leading to stock price fluctuations. The company plans to issue Series A and Series B warrants, with exercise prices of $0.48 and $0.55, respectively. This news attracted market attention, causing trading volume to surge, with the stock initially rising by 53.53% in pre-market but then retreating.
    
2.  On April 27, OSE Immunotherapeutics' partner Veloxis received FDA orphan drug designation for the prevention of heart transplant rejection. Although this news is not directly related to Scinai Immunotherapeutics, it may impact overall sentiment in the biotechnology industry. The biotechnology sector has been volatile recently, and policy changes should be monitored.
    

**Top Gainers in Pre-market US Stocks**

Direct Digital is up 45.22% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation.

Calidi Biotherapeutics is up 39.24% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation.

Profusa is up 28.36% in pre-market trading. There is no significant news recently; trading is active, and capital flows are evident. Considering sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. no\_news

### Related Stocks

- [POET.US](https://longbridge.com/en/quote/POET.US.md)
- [SCNI.US](https://longbridge.com/en/quote/SCNI.US.md)
- [DRCT.US](https://longbridge.com/en/quote/DRCT.US.md)
- [CLDI.US](https://longbridge.com/en/quote/CLDI.US.md)
- [PFSA.US](https://longbridge.com/en/quote/PFSA.US.md)

## Related News & Research

- [Why Poet Technologies stock skyrocketed this week](https://longbridge.com/en/news/286681063.md)
- [POET Technologies surges after $50 million purchase order to launch partnership for new AI infrastructure](https://longbridge.com/en/news/286417793.md)
- [POET Technologies GAAP EPS of -$0.08 misses by $0.03, revenue of $0.5M beats by $0.25M](https://longbridge.com/en/news/286510324.md)
- [POET Technologies Posts Higher Q1 2026 Revenue but Swings to Net Loss as Costs Surge](https://longbridge.com/en/news/286588263.md)
- [POET Stock Jumped on $500 Million Deal With Lumilens. Its Financials Have a Long Way to Go.](https://longbridge.com/en/news/286600014.md)